Chemo plus immunotherapy vs chemo alone before colon cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of colon cancer called adenocarcinoma that has not spread to other organs and is at a stage where surgery is possible.
- The tumor is at least T3 (invading deep into the colon wall) or T4, and may have other risk factors like lymph node involvement or blood vessel invasion.
- You have not received any prior treatment for colon cancer (like chemotherapy or radiation).
- You are between 18 and 75 years old, and your general health is good (able to do daily activities without help).
- Your tumor is 'pMMR' or 'MSS' (a genetic marker that makes it likely to respond to immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests whether giving chemotherapy before surgery can improve outcomes for people with colon cancer that has grown into nearby tissue or lymph nodes but hasn't spread to other organs. It is for patients whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
This trial tests whether giving radiation therapy along with standard chemotherapy before surgery can help shrink advanced colon cancer that has grown through the bowel wall but hasn't spread to other organs. It is for a specific type of colon cancer called pMMR/MSS.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy (XELOX) given before surgery for Stage III colon cancer that is pMMR or MSS. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.